Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
- Research Site
-
-
California
-
Los Angeles, California, United States
- Research Site
-
San Francisco, California, United States
- Research Site
-
Spring Valley, California, United States
- Research Site
-
Walnut Creek, California, United States
- Research Site
-
-
Maryland
-
Bethesda, Maryland, United States
- Research Site
-
-
Texas
-
Austin, Texas, United States
- Research Site
-
San Antonio, Texas, United States
- Research Site
-
-
Virginia
-
Richmond, Virginia, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent
- Type 2 Diabetes
- BMI 27-42
- Specified diet/exercise and/or diabetes medications
Exclusion Criteria:
- BP > 150/95
- Stroke/MI/unstable cardiovascular disease within 6 months
- Clinically significant renal, hepatic, or psychiatric disease
- Unstable thyroid disease or replacement therapy
- Nephrolithiasis
- Obesity of known genetic or endocrine origin
- Participation in a formal weight loss program or lifestyle intervention
- History of glaucoma
- Pregnancy or breastfeeding
- Alcohol abuse
- Eating disorder
- Excluded medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Phentermine 15mg/topiramate 100mg
|
phentermine 15mg/topiramate 100mg
|
|
Placebo Comparator: 2
Matched placebo
|
matched placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in HbA1c at Week 28.
Time Frame: Baseline to 28 weeks
|
Baseline to 28 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Absolute Weight Change (kg) From Baseline to Week 28
Time Frame: Baseline to 28 weeks
|
Baseline to 28 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OB-202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.